当前位置： SCI文献检索 > JAPANESE JOURNAL OF CLINICAL ONCOLOGY期刊下所有文献 > Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.

Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.

Abstract：

BACKGROUND:Programmed death-ligand 1 is an immune modulator that promotes immunosuppression by binding to programmed death-1 of T-lymphocytes. Whereas programmed death-ligand 1 expression has been shown to be associated with the clinical response to anti-programmed death-ligand 1 antibody, the association of tumor programmed death-ligand 1 expression with clinicopathological/molecular features and with prognosis remains inconclusive in lung adenocarcinoma. We therefore examined the association of programmed death-ligand 1 expression with the clinicopathological/molecular features and prognosis of lung adenocarcinoma. METHODS:Using tissue microarrays of 268 consecutive cases of lung adenocarcinoma, we evaluated programmed death-ligand 1 expression by immunohistochemistry. We examined the association of programmed death-ligand 1 expression with clinicopathological and molecular features. We also examined the prognostic association of programmed death-ligand 1 expression, using the log-rank test as well as Cox proportional hazards regression models to compute the mortality hazard ratio (HR). RESULTS:Programmed death-ligand 1 immunoreactivity (at least 5% of the tumor cells) was observed in 43 (16%) of 268 cases of lung adenocarcinoma. Programmed death-ligand 1 positivity was associated with less tumor differentiation (P < 0.0001) and EGFR wild-type status (P = 0.0008). In a multivariable logistic regression analysis, less tumor differentiation was independently associated with programmed death-ligand 1 positivity (multivariable odds ratio, 6.54; 95% confidence interval [CI], 2.37-23.3; P = 0.0001). Programmed death-ligand 1 positivity was associated with a poor prognosis for lung cancer-specific survival (log-rank, P = 0.019; HR, 1.73; 95% CI, 1.06-2.72; P = 0.030) and overall survival (log-rank, P = 0.0014; HR, 1.88; 95% CI, 1.25-2.74). CONCLUSION:Our study demonstrated that programmed death-ligand 1 positivity in lung adenocarcinoma was associated with less tumor differentiation and EGFR wild-type status, as well as a poor prognosis.

journal_name

Jpn J Clin Oncol

journal_title

Japanese journal of clinical oncology

authors

Inamura K,Yokouchi Y,Sakakibara R,Kobayashi M,Subat S,Ninomiya H,Nagano H,Nomura K,Okumura S,Ishikawa Y

doi

10.1093/jjco/hyw087

subject

Has Abstract

pub_date

2016-10-01 00:00:00

pages

935-941

issue

eissn

0368-2811

issn

1465-3621

pii

hyw087

journal_volume

pub_type

杂志文章

在线工具

Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.